Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
'These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer,' said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. 'We continue to be driven by our mission to provide physicians and their patients better tools for guiding treatment through earlier, more sensitive, and more accurate detection of residual and recurrent cancer.'
The presentations are as follows (all times CDT):
Clinical Science Symposium: Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial)
Session: Breast Cancer
Time:
Location: Arie Crown Theater/Live Stream
Presenter: Natasha Hunter, MD, University of Washington
Oral Presentation: Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
Session: Gynecologic Cancer
Time: June 2, 2025, 8:48 AM - 9:00 AM
Location: Room S100a (Grand Ballroom) - McCormick Place South (Level 1)/Live Stream
Presenter: Jyoti Mayadev, MD, University of California San Diego Medical Center
Poster Presentation: Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC)
Session: Breast Cancer—Local/Regional/Adjuvant
Time: June 2, 2025, 9:00 AM - 12:00 PM
Location: Hall A, poster bd 145 - McCormick Place South (Level 1)
Presenter: Luc Cabel, MD, PhD, Institut Curie, Paris, France
Poster Presentation: Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer
Session: Developmental Therapeutics—Immunotherapy
Time: June 2, 2025, 1:30 PM - 4:30 PM
Location: Hall A, poster bd 208 - McCormick Place South (Level 1)
Presenter: Charles Abbott, PhD, Personalis, Inc., Fremont, CA
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect residual and recurrent cancer earlier, more sensitively, and more accurately, guide treatment, monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the presentations and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
Not affiliated with or endorsed by ASCO.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating
United Therapeutics Corporation (NASDAQ:UTHR) is one of the high-margin pharma stocks to buy now. Morgan Stanley has lowered its price target on United Therapeutics (NASDAQ: UTHR) to $328 from $348, while maintaining an Equal Weight rating, amid broader headwinds facing the biotech and pharmaceutical sectors. The firm flagged persistent macroeconomic challenges and regulatory uncertainties that continue to weigh on investor sentiment across the space. A team of scientists in a laboratory, running tests on a biotechnology product. In a research note to clients, the firm pointed to several factors pressuring large-cap healthcare names this year, including policy volatility around drug pricing, ongoing debates over international transfer pricing, and staffing turnover at the FDA. Against that backdrop, United Therapeutics is facing specific questions about near-term sales performance, particularly around its key pulmonary arterial hypertension therapy, Tyvaso. Morgan Stanley is now modeling second-quarter Tyvaso sales of $442 million, below the Street consensus of $483 million. Total revenue is expected to reach $768 million, also under consensus estimates of $805 million. The firm attributes the cautious outlook to potential softness in Tyvaso DPI uptake and less momentum in patient onboarding than previously projected. Despite strong fundamentals and long-term growth driver, including its organ manufacturing pipeline, Morgan Stanley appears to be taking a more conservative stance in the near term. With shares already reflecting much of the upside potential, the firm sees a more balanced risk-reward profile at current levels. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
21 hours ago
- Yahoo
Do You Believe in the Growth Potential of Tempus AI (TEM)?
Patient Capital Management, a value investing firm, released its 'Patient Capital Opportunity Equity Strategy' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy generated a total return of 15.3% net of fees in the quarter compared to the strategy's unmanaged benchmark, the S&P 500 Index's 10.9% return. According to a three-factor performance attribution model, the selection effect contributed positively to the portfolio's performance, which was partially offset by allocation and interaction effects. In addition, you can check the fund's top 5 holdings to know its best picks in 2025. In its second quarter 2025 investor letter, Patient Capital Opportunity Equity Strategy highlighted stocks such as Tempus AI, Inc. (NASDAQ:TEM). Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company. The one-month return of Tempus AI, Inc. (NASDAQ:TEM) was -11.21%, and its shares gained 46.50% of their value over the last 52 weeks. On July 17, 2025, Tempus AI, Inc. (NASDAQ:TEM) stock closed at $60.65 per share, with a market capitalization of $10.382 billion. Patient Capital Opportunity Equity Strategy stated the following regarding Tempus AI, Inc. (NASDAQ:TEM) in its second quarter 2025 investor letter: "Tempus AI, Inc. (NASDAQ:TEM), is a leading precision medicine platform focused on transforming cancer care through data and artificial intelligence (AI). The business operates across three synergistic segments – genomics, data and services, and AI applications – that together reinforce its competitive moat. These segments feed into one another, enabling Tempus to build one of the world's largest molecular databases of cancer patients. Leveraging this library, the company is embedding AI into diagnostic workflows to drive more personalized, data-driven treatment decisions. Though still early in its lifecycle, Tempus is on track to surpass $1B in revenue within its first decade and expects to achieve EBITDA profitability this year, an important milestone. While oncology remains its core market today, the company is expanding into other areas like cardiology, neuropsychology, and radiology. We believe healthcare is primed for disruption through AI and Tempus is well positioned to take advantage. We have high conviction in its ability to continue winning new business, expanding its database, and achieving profitability." A doctor administering a diagnostic test kit for the detection of gastrointestinal diseases. Tempus AI, Inc. (NASDAQ:TEM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Tempus AI, Inc. (NASDAQ:TEM) at the end of the first quarter, compared to 17 in the previous quarter. In the first quarter of 2025, Tempus AI, Inc.'s (NASDAQ:TEM) revenue increased 75.4% year-over-year to $255.7 million. While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Tempus AI, Inc. (NASDAQ:TEM) and shared the list of top 10 AI infrastructure stocks to buy. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Key Points Shares of Viking Therapeutics soared last year on high hopes for its obesity drug VK2735. The stock stumbled beginning in November of last year, however, seemingly on concerns over manufacturing costs. In retrospect, this action mirrors a pattern dished out by other biopharma names in similar situations, often leading to a rally. 10 stocks we like better than Viking Therapeutics › Any investor who owned Viking Therapeutics (NASDAQ: VKTX) before November of last year is sure to be disappointed and maybe even a little worried. Shares are down nearly 60% since October last year and lower to the tune of 68% from their early 2024 high after soaring in 2023. Yikes. If you were on this wild ride, don't panic yet. And for interested newcomers, the sell-off may arguably be a buying opportunity. Here's why: History says this kind of sharp rise and fall in biopharma stock prices often precedes a slower but more even and more-rewarding rally. But first things first. What's Viking Therapeutics? Never heard of it? It wouldn't be surprising if you hadn't. Its $3.5 billion market cap doesn't turn many heads. It's a pre-revenue company too, which of course means it's also pre-profit. That doesn't mean it's not worth owning even if it is inherently risky -- and volatile. It just means you'll want to handle it differently if you choose to handle it at all. And you just might want to, given Viking's developmental pipeline. This company's currently testing four different drugs in five different clinical trials, each of which is aimed at relatively rare metabolic and endocrine disorders. Its highest-profile drug is also the one that's furthest along the developmental trail. That's an injectable form of an anti-obesity drug currently referred to as VK2735. Its molecular structure is similar to that of the approved GLP-1 weight-loss drugs Ozempic from Novo Nordisk (NYSE: NVO) and Eli Lilly's (NYSE: LLY) Zepbound. In fact, the differences are significant enough to avoid patent infringement challenges. VK2735 began phase 3 testing earlier this year, which is the final stage of trials necessary before the U.S. Food and Drug Administration (FDA) makes its ultimate approval decision. And this is a big reason Viking Therapeutics has been so volatile since 2022. As the drug in question has worked its way through the lengthy testing process, investors have pre-emptively purchased shares in anticipation of good news. However, as is so often the case with biopharma stocks of companies working on game-changing drugs, the market has overshot its target more than once and then suffered a sizable setback. That's what happened beginning in November of last year, anyway. The company announced solid testing results for VK2735. But the market panicked over concerns that manufacturing the phase 2 drug therapy's injectable version and an orally administered version simultaneously could prove quite costly. The stock's been pressured lower ever since, even though the underlying story hasn't actually changed much in the meantime. The fickle crowd trading this stock has simply decided to see the glass as half-empty rather than half-full. It happens. The thing is, it's not like this same story hasn't played out many times within the biopharma realm. When the drug in question is the real deal though, a recovery typically takes shape, eventually carrying the ticker in question to much higher highs. One doesn't need to look that far back in time to see that transpire. An all-too-common tale for biopharma stocks Take Regeneron Pharmaceuticals (NASDAQ: REGN) as an example. Although it's got a handful of drugs in its portfolio, eczema and asthma treatment Dupixent is its breadwinner, making up the single-biggest source of Regeneron's revenue. Eylea is a respectable close second; there is no close third. The ongoing sales growth of both drugs is a big reason this stock gained so much between late 2019 and late last year. Hope for both was also the reason Regeneron shares soared between 2010 and 2015. There was a stretch of time between 2015 and 2019, however, when shares just weren't finding any traction even though Dupixent was approved to treat atopic dermatitis in 2017 and won its approval as an asthma treatment in 2018. It took a handful of more approvals of Dupixent through 2021 to light a lasting fire under the stock. Then there's Exelixis (NASDAQ: EXEL). This stock went nowhere between 2017 and 2023 but has doubled in value since then thanks to the rapid sales growth of its oncology drug Cabometyx. In fact, its revenue reached $511 million last quarter versus $376 million for the comparable quarter a year earlier. The thing is, Cabometyx was actually first approved by the FDA back in 2016 and won several more approvals through 2021 that started driving real sales growth that same year. The market just chose to sit on the fence for a couple more years. If you need more examples of biopharma stocks that climbed and fell out of sync despite the progress being made by the company, there are many more -- Iovance Therapeutics, ACADIA Pharmaceuticals, and CRISPR Therapeutics are just to name a few. It happens all the time. The bigger point is, there's a frequent disconnect between a biopharma company's stock and that biopharma company's developmental and fiscal progress. Often times, investors plow in too much and too soon. At other times, they're surprisingly late, perhaps wary of another market pullback. When the drug in question shows true potential, sooner or later the market figures it out and properly prices in its success, as it did for Regeneron and Exelixis. If you're diving in, at least worry about the right things But aren't Novo Nordisk and Eli Lilly already established players with very similar obesity drugs? Fair enough. Just know that consumers are often quite willing to try "something else," particularly if it's easier, cheaper, faster, or more convenient than established alternatives. And with Morgan Stanley's prediction that the global weight-loss drug market could swell from last year's $15 billion to a peak of $150 billion by 2035, there's arguably more than enough business -- and growth -- to make Viking Therapeutics' VK2735 a smashing success. But probably not immediately. And that's where patience comes to the forefront. As we often say at The Motley Fool, if you are convinced about the company's business fundamentals, hold its stock for at least three years. Viking's stock should eventually rally, most likely within a two-year time frame. After all, it shouldn't take nearly that long to at least start getting meaningful updates on the weight-loss drug's phase 3 testing. Perhaps the bigger concern here should be the potential cost of manufacturing VK2735 in both an injectable and an oral form. Even then, in light of Morgan Stanley's forecasted demand, the potential cost of simultaneously manufacturing two competing drugs seems like a modest hill to climb. Most investors are arguably too worried about that possibility. Perhaps they were just looking for the right justification to take profits on last year's red-hot run-up... a justification that has since run its course. On that note, just remember this is still a volatile small-cap biopharma name with a speculative crowd of followers. You'll only want to dive in if you're sure you've got the patience and can handle the tricky navigation this name will almost certainly require. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics, Exelixis, Iovance Biotherapeutics, and Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
